Gabe S. Sonke
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
2016/12/20 by Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke +10 · 4 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer-related Molecular Pathways #Ovarian cancer diagnosis and treatment #Renal and related cancers
- Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
2022/10/11 by Maaike A. C. Bruin, Gabe S. Sonke, Jos H. Beijnen +1 · 2 citations
Medicine · #PARP inhibition in cancer therapy